资源类型

期刊论文 15

年份

2022 1

2021 4

2020 3

2019 2

2016 1

2015 2

2013 1

展开 ︾

关键词

COVID-19 1

SARS-CoV-2 1

中药 1

抗体应答 1

抗病毒 1

新冠病毒肺炎 1

死亡率 1

病毒载量 1

细胞因子 1

细胞因子风暴 1

肺纤维化 1

展开 ︾

检索范围：

排序： 展示方式：

Beneficial metabolic activities of inflammatory cytokine interleukin 15 in obesity and type 2 diabetes

null

《医学前沿（英文）》 2015年 第9卷 第2期   页码 139-145 doi: 10.1007/s11684-015-0377-z

摘要：

In obesity, chronic inflammation is believed to induce insulin resistance and impairs adipose tissue function. Although this view is supported by a large body of literature, it has been challenged by growing evidence that pro-inflammatory cytokines may favor insulin sensitivity through induction of energy expenditure. In this review article, interleukin 15 (IL-15) is used as a new example to explain the beneficial effects of the pro-inflammatory cytokines. IL-15 is secreted by multiple types of cells including macrophages, neutrophils and skeletal muscle cells. IL-15 expression is induced in immune cells by endotoxin and in muscle cells by physical exercise. Its transcription is induced by transcription factor NF-κB. IL-15 binds to its receptor that contains three different subunits (α, β and γ) to activate JAK/STAT, PI3K/Akt, IKK/NF-κB and JNK/AP1 pathways in cells. In the regulation of metabolism, IL-15 reduces weight gain without inhibiting food intake in rodents. IL-15 suppresses lipogenesis, stimulates brown fat function, improves insulin sensitivity through weight loss and energy expenditure. In human, circulating IL-15 is negatively associated with body weight. In the immune system, IL-15 stimulates proliferation and differentiation of T cells, NK cells, monocytes and neutrophils. In the anti-obesity effects of IL-15, T cells and NK cells are not required, but leptin receptor is required. In summary, evidence from human and rodents supports that the pro-inflammatory cytokine IL-15 may enhance energy expenditure to protect the body from obesity and type 2 diabetes. The mechanism of IL-15 action remains to be fully uncovered in the regulation of energy expenditure.

关键词： inflammation     obesity     cytokine     energy expenditure     insulin resistance    

HTML PDF 收藏

Cytokine storm and translating IL-6 biology into effective treatments for COVID-19

《医学前沿（英文）》 doi: 10.1007/s11684-023-1044-4

摘要： As of May 3, 2023, the coronavirus disease 2019 (COVID-19) pandemic has resulted in more than 760 million confirmed cases and over 6.9 million deaths. Several patients have developed pneumonia, which can deteriorate into acute respiratory distress syndrome. The primary etiology may be attributed to cytokine storm, which is triggered by the excessive release of proinflammatory cytokines and subsequently leads to immune dysregulation. Considering that high levels of interleukin-6 (IL-6) have been detected in several highly pathogenic coronavirus-infected diseases, such as severe acute respiratory syndrome in 2002, the Middle East respiratory syndrome in 2012, and COVID-19, the IL-6 pathway has emerged as a key in the pathogenesis of this hyperinflammatory state. Thus, we review the history of cytokine storm and the process of targeting IL-6 signaling to elucidate the pivotal role played by tocilizumab in combating COVID-19.

关键词： SARS-CoV-2     COVID-19     cytokine storm     interleukin-6     tocilizumab    

HTML PDF 收藏

Inflammation and liver tumorigenesis

null

《医学前沿（英文）》 2013年 第7卷 第2期   页码 242-254 doi: 10.1007/s11684-013-0256-4

摘要：

Inflammation has been considered as one of the hallmarks of cancer, and chronic hepatitis is a major cause of liver cancer. This review will focus on the pathogenic role of inflammation in hepatocarcinogenesis and will discuss recent advances in understanding the chronic hepatitis-liver cancer link based on hot spots in liver cancer research, including cellular interaction, cytokines, microRNA and stem cells. All of these mechanisms should be taken into consideration because they are crucial for the development of more efficacious therapeutic strategies for preventing and treating human chronic hepatitis and hepatocellular carcinoma.

关键词： hepatocellular carcinoma     hepatitis     cytokine     stem cell     miRNA    

HTML PDF 收藏

High-affinity T cell receptors redirect cytokine-activated T cells (CAT) to kill cancer cells

Synat Kang, Yanyan Li, Yifeng Bao, Yi Li

《医学前沿（英文）》 2019年 第13卷 第1期   页码 69-82 doi: 10.1007/s11684-018-0677-1

摘要：

Cytokine-activated T cells (CATs) can be easily expanded and are widely applied to cancer immunotherapy. However, the good efficacy of CATs is rarely reported in clinical applications because CATs have no or very low antigen specificity. The low-efficacy problem can be resolved using T cell antigen receptor-engineered CAT (TCR-CAT). Herein, we demonstrate that NY-ESO-1157–165 HLA-A*02:01-specific high-affinity TCR (HAT)-transduced CATs can specifically kill cancer cells with good efficacy. With low micromolar range dissociation equilibrium constants, HAT-transduced CATs showed good specificity with no off-target killing. Furthermore, the high-affinity TCR-CATs delivered significantly better activation and cytotoxicity than the equivalent TCR-engineered T cells (TCR-Ts) in terms of interferon-g and granzyme B production and in vitro cancer cell killing ability. TCR-CAT may be a very good alternative to the expensive TCR-T, which is considered an effective personalized cyto-immunotherapy.

关键词： cytokine-activated T cells     high-affinity T cell receptor     cancer immunotherapy     TCR-CAT    

HTML PDF 收藏

Molecular characterization of two suppressor of cytokine signaling 1 genes (

Xue XU,Jiannan ZHANG,Juan LI,Yajun WANG

《农业科学与工程前沿（英文）》 2015年 第2卷 第1期   页码 73-83 doi: 10.15302/J-FASE-2015044

摘要： Suppressor of cytokine signaling 1 (SOCS1) protein can inhibit the signal transduction triggered by some cytokines or hormones and thus are important in many physiological/pathological processes, including innate and adaptive immunity, inflammation, and development in mammals. However, there is sparse information about their structure, tissue expression, in birds, where their biological functions remain unknown. In this study, we cloned and characterized two genes (named and ) from chickens. is predicted to encode a 207-amino acid protein, which shares high amino acid sequence identity (64%–67%) with human and mouse SOCS1. Besides , a novel gene was also identified in chickens and other non-mammalian vertebrates including . Chicken is predicted to encode a 212-amino acid protein, which shares only 30%–32% amino acid sequence identity with human SOCS1 and cSOCS1a. RT-PCR assay revealed that both and are widely expressed in all chicken tissues. Using a luciferase reporter assay system, we further demonstrated that transient expression of and can significantly inhibit chicken growth hormone (GH)- or prolactin (PRL)-induced luciferase activities of Hep G2 cells expressing cGH receptor (or cPRL receptor), indicating that SOCS1a and SOCS1b proteins can negatively regulate GH/PRL signaling. Taken together, these data suggest that both cSOCS1a and cSOCS1b may function as negative regulators of cytokine/hormone actions, such as modulation of GH/PRL actions in chickens.

关键词： chicken     SOCS1a     SOCS1b     growth hormone     prolactin    

HTML PDF 收藏

Management of cytokine release syndrome related to CAR-T cell therapy

Hongli Chen, Fangxia Wang, Pengyu Zhang, Yilin Zhang, Yinxia Chen, Xiaohu Fan, Xingmei Cao, Jie Liu, Yun Yang, Baiyan Wang, Bo Lei, Liufang Gu, Ju Bai, Lili Wei, Ruili Zhang, Qiuchuan Zhuang, Wanggang Zhang, Wanhong Zhao, Aili He

《医学前沿（英文）》 2019年 第13卷 第5期   页码 610-617 doi: 10.1007/s11684-019-0714-8

摘要： Chimeric antigen receptor T (CAR-T) cell therapy is a novel cellular immunotherapy that is widely used to treat hematological malignancies, including acute leukemia, lymphoma, and multiple myeloma. Despite its remarkable clinical effects, this therapy has side effects that cannot be underestimated. Cytokine release syndrome (CRS) is one of the most clinically important and potentially life-threatening toxicities. This syndrome is a systemic immune storm that involves the mass cytokines releasing by activated immune cells. This phenomenon causes multisystem damages and sometimes even death. In this study, we reported the management of a patient with recurrent and refractory multiple myeloma and three patients with acute lymphocytic leukemia who suffered CRS during CAR-T treatment. The early application of tocilizumab, an anti-IL-6 receptor antibody, according to toxicity grading and clinical manifestation is recommended especially for patients who suffer continuous hyperpyrexia, hypotensive shock, acute respiratory failure, and whose CRS toxicities deteriorated rapidly. Moreover, low doses of dexamethasone (5–10 mg/day) were used for refractory CRS not responding to tocilizumab. The effective management of the toxicities associated with CRS will bring additional survival opportunities and improve the quality of life for patients with cancer.

关键词： chimeric antigen receptor T cell     cytokine release syndrome     tocilizumab    

HTML PDF 收藏

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients

《医学前沿（英文）》 2022年 第16卷 第2期   页码 285-294 doi: 10.1007/s11684-021-0843-8

摘要： Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has shown impressive efficacy in treating B-cell malignancies. A single-center phase I dose-escalation study was conducted to evaluate the safety and efficacy of T cells transduced with CBM.CD19 CAR, a second-generation anti-CD19 CAR bearing 4-1BB costimulatory molecule, for the treatment of patients with refractory diffuse large B-cell lymphoma (DLBCL). Ten heavily treated patients with refractory DLBCL were given CBM.CD19 CAR-T cell (C-CAR011) treatment. The overall response rate was 20% and 50% at 4 and 12 weeks after the infusion of C-CAR011, respectively, and the disease control rate was 60% at 12 weeks after infusion. Treatment-emergent adverse events occurred in all patients. The incidence of cytokine release syndrome in all grades and grade≥3 was 90% and 0, respectively, which is consistent with the safety profile of axicabtagene ciloleucel and tisagenlecleucel. Neurotoxicity or other dose-limiting toxicities was not observed in any dose cohort of C-CAR011 therapy. Antitumor efficacy was apparent across dose cohorts. Therefore, C-CAR011 is a safe and effective therapeutic option for Chinese patients with refractory DLBCL, and further large-scale clinical trials are warranted.

关键词： CAR-T cell therapy     refractory diffuse large B-cell lymphoma     cytokine release syndrome     dose-limiting toxicity    

HTML PDF 收藏

The relationship between progesterone and Th-related cytokines in plasma during early pregnancy in cows

Lei CHENG,Youdong XIN,Xiaohua LIU,Xiuzhong HU,Min XIANG,Dingfa WANG,Shuhong ZHAO

《农业科学与工程前沿（英文）》 2016年 第3卷 第2期   页码 147-152 doi: 10.15302/J-FASE-2016099

摘要： In cows, progesterone (P4) is essential for the maintenance of pregnancy and successful embryo development is dependent on the maternal immunomodulation of Th-related cytokines. However, investigation of the relationship between P4 and Th immunity in cattle remains incomplete. Therefore, we evaluated plasma P4 concentrations and expressions of three Th-related cytokines, interleukins IL-1β, IL-4 and IL-6, in 15 pregnant and 11 non-pregnant cows 0, 14, 18, 21, and 28 d post artificial insemination. Pregnant cows had significantly higher plasma P4 levels and pregnant cows with higher P4 on 14 d tended to have higher P4 in the subsequent period of pregnancy. There was no difference in IL-4 and IL-6 expression between pregnant cows and non-pregnant cows, whereas plasma IL-1β was temporally upregulated on 21 d. The cytokines measured were not affected in either the high-P4 group (>11.1 ng·mL ) or the low-P4 group (<11.1 ng·mL ) in pregnant cows. A weak negative correlation between IL-1β and IL-6 was observed, but none of the cytokines was associated with a change in plasma P4. In conclusion, there was no clear relationship between P4 and Th immunity in maternal plasma in the pregnant cows, which differs from what occurs in humans and mice during early pregnancy.

关键词： dairy cow     progesterone     pregnancy     cytokine    

HTML PDF 收藏

人工肝血液净化系统——一种针对COVID-19细胞因子风暴的有效救治方法

章益民, 俞亮, 汤灵玲, 朱梦飞, 金燕琪, 王周晗, 李兰娟

《工程（英文）》 2021年 第7卷 第1期   页码 11-13 doi: 10.1016/j.eng.2020.03.006

HTML PDF 收藏

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

《医学前沿（英文）》 2020年 第14卷 第6期   页码 711-725 doi: 10.1007/s11684-020-0808-3

摘要： The combination of the immunotherapy (i.e., the use of monoclonal antibodies) and the conventional chemotherapy increases the long-term survival of patients with lymphoma. However, for patients with relapsed or treatment-resistant lymphoma, a novel treatment approach is urgently needed. Chimeric antigen receptor T (CAR-T) cells were introduced as a treatment for these patients. Based on recent clinical data, approximately 50% of patients with relapsed or refractory B-cell lymphoma achieved complete remission after receiving the CD19 CAR-T cell therapy. Moreover, clinical data revealed that some patients remained in remission for more than two years after the CAR-T cell therapy. Other than the CD19-targeted CAR-T, the novel target antigens, such as CD20, CD22, CD30, and CD37, which were greatly expressed on lymphoma cells, were studied under preclinical and clinical evaluations for use in the treatment of lymphoma. Nonetheless, the CAR-T therapy was usually associated with potentially lethal adverse effects, such as the cytokine release syndrome and the neurotoxicity. Therefore, optimizing the structure of CAR, creating new drugs, and combining CAR-T cell therapy with stem cell transplantation are potential solutions to increase the effectiveness of treatment and reduce the toxicity in patients with lymphoma after the CAR-T cell therapy.

关键词： chimeric antigen receptor T (CAR-T) cell     lymphoma     cytokine release syndrome (CRS)     immune effector cell-associated neurotoxicity syndrome (ICANS)    

HTML PDF 收藏

Keratin 5-Cre-driven deletion of

Jun Yang, Lianqing Wang, Yingzhi Huang, Keqiang Liu, Chaoxia Lu, Nuo Si, Rongrong Wang, Yaping Liu, Xue Zhang

《医学前沿（英文）》 2020年 第14卷 第3期   页码 305-317 doi: 10.1007/s11684-019-0722-8

摘要： Familial acne inversa (AI) is an autoinflammatory disorder that affects hair follicles and is caused by loss-of-function mutations in -secretase component genes. We and other researchers showed that ( ) is the most frequently mutated gene in familial AI. In this study, we generated a keratin 5-Cre-driven epidermis-specific conditional knockout mutant in mice. We determined that this mutant recapitulated the major phenotypes of AI, including hyperkeratosis of hair follicles and inflammation. In mice, the IL-36a expression level markedly increased starting from postnatal day 0 (P0), and this increase occurred much earlier than those of TNF- , IL-23A, IL-1 and TLR4. RNA-Seq analysis indicated that Sprr2d, a member of the small proline-rich protein 2 family, in the skin tissues of the mice was also upregulated on P0. Quantitative reverse-transcription polymerase chain reaction showed that other genes had a similar expression pattern. Our findings suggested that IL-36a might be a key inflammatory cytokine in the pathophysiology of AI and involved in the malfunction of the skin barrier in the pathogenesis of AI.

关键词： acne inversa mouse model     interleukin 1 family     member 6     small proline rich protein 2D     key inflammatory cytokine    

HTML PDF 收藏

Endothelial dysfunction in COVID-19 calls for immediate attention: the emerging roles of the endothelium in inflammation caused by SARS-CoV-2

Weijian Hang, Chen Chen, Xin A. Zhang, Dao Wen Wang

《医学前沿（英文）》 2021年 第15卷 第4期   页码 638-643 doi: 10.1007/s11684-021-0831-z

摘要： The COVID-19 pandemic has caused numerous deaths around the world. A growing body of evidence points to the important role of overwhelming inflammatory responses in the pathogenesis of COVID-19 and the effectiveness of anti-inflammation therapy against COVID-19 is emerging. In addition to affecting the lungs, COVID-19 can be a severe systemic inflammatory disease that is related to endothelial dysfunction. We are calling for closer attention to endothelial dysfunction in COVID-19 not only for fully revealing the pathogenic mechanism of COVID-19 but also for properly adjusting the strategy of clinical intervention.

关键词： COVID-19     endothelial dysfunction     inflammation reaction     cytokine storm    

HTML PDF 收藏

中药治疗新冠病毒肺炎的科学基础 Perspective

梁丽娴, 潘胡丹, 黄虞枫, 范星星, 王婉莹, 何芳, 蔡俊, 周华, 刘良

《工程（英文）》 2020年 第6卷 第10期   页码 1099-1107 doi: 10.1016/j.eng.2020.08.009

摘要：

新近暴发的新冠病毒肺炎（COVID-19）已成为危害全球健康的紧急事件。现有证据表明，新冠病毒（SARS-CoV-2）与其他冠状病毒（如SARS-CoV和MERS-CoV）的基因序列具有相似性。因此， 针对现存冠状病毒的引发疾病的机制研究和在治疗SARS时所取得的经验和教训，可咨今天对抗新冠病毒引发疾病的参考。COVID-19患者的临床病理特征提示患者在病情进展过程中通常会经历五个发展阶段：大量病毒感染、免疫系统抑制、细胞因子风暴、多器官损伤及后期的肺纤维化样改变， 严重者常导致死亡。早期阻断疾病进展是取得治疗成功的关键。但是，目前尚无针对COVID-19的 特效药物或疫苗，世界卫生组织（WHO）正敦促尽快建立新型预防和治疗策略。传统中医药（TCM） 对于疫病的防治的实践已经积累了几千年的有用经验，它通过整体调节机体功能发挥疗效。在此次疫情中，中医药作为替代治疗或与西药联合使用，在疫情防控中发挥了重要的作用。本文总结了此次抗疫过程中中国国家和省级机构推荐使用的中药复方和中成药的潜在用途和治疗机制，以期发现其治疗COVID-19的潜在科学内涵。同时，整合应用多种组学及转化医学技术开展基础与临床研究有望进一步证实中药复方的治疗机制。

关键词： COVID-19     SARS-CoV-2     中药     抗病毒     细胞因子风暴     肺纤维化    

HTML PDF 收藏

新冠病毒肺炎抗体应答、细胞因子的动态变化及其与生存状况的关联 ——一项回顾性队列研究 Article

刘莉, 陈亨贵, 李莹, 李辉军, 李娇元, 王意, 姚霜, 秦川, 童书韬, 袁旭, 罗霞, 缪小平, 潘安, 刘争, 程黎明

《工程（英文）》 2021年 第7卷 第7期   页码 958-965 doi: 10.1016/j.eng.2021.04.015

摘要：

目前，患者感染严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）后，机体免疫状况随时间的纵向变化及其与临床结局的关联尚不明确。因此，我们致力于研究新冠病毒特异性抗体[免疫球蛋白G（IgG）和免疫球蛋白M（IgM）]随时间变化的特征，并分析特异性抗体、炎性细胞因子及其与新冠病毒肺炎（COVID-19，简称新冠肺炎）患者的生存状况之间的关联。研究共招募了1830例实验室确诊的新冠肺炎感染病例。利用局部加权回归散点平滑法（LOWESS）拟合患者自发病以来直至12周的病毒载量、特异性抗体及细胞因子水平随时间的变化谱。通过中介分析，探究细胞因子在抗体应答与生存状况之间的中介效应。在1830例患者中，新冠病毒核酸阳性患者共1435例，新冠病毒特异性IgG和（或）IgM抗体阳性患者为395例。在1435例患者中，2.4%的患者在住院期间既未出现IgG也未出现IgM的血清学转变。特异性IgG和IgM的血清阳性率在发病后的第1周分别为29.6%和48.1%，并在5周内达到峰值。对于痊愈出院患者组，在发病后的12周内，IgM水平缓慢下降，而IgG水平基本维持在188 AU· mL−1左右。反之，对于最终进展为死亡的患者，其IgM水平迅速下降，IgG水平在第12周也下降至87 AU· mL−1。与出院患者组相比，病亡患者组的白细胞介素6（IL-6）、白细胞介素8（IL-8）、白细胞介素10（IL-10）、白细胞介素1β（IL-1β）、白细胞介素2受体（IL-2R）及肿瘤坏死因子-α（TNF-α）水平均较高，IgG水平与死亡风险之间12.5%的关联由上述细胞因子介导。本研究阐明了新冠病毒特异性抗体自发病以来12周内的实时变化特征，并表明了抗体应答对生存结局的积极作用，相关发现对新冠肺炎患者的预后评估可能有所帮助。

关键词： 新冠病毒肺炎     抗体应答     细胞因子     死亡率     病毒载量    

HTML PDF 收藏

Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial

Dongsheng Wang, Binqing Fu, Zhen Peng, Dongliang Yang, Mingfeng Han, Min Li, Yun Yang, Tianjun Yang, Liangye Sun, Wei Li, Wei Shi, Xin Yao, Yan Ma, Fei Xu, Xiaojing Wang, Jun Chen, Daqing Xia, Yubei Sun, Lin Dong, Jumei Wang, Xiaoyu Zhu, Min Zhang, Yonggang Zhou, Aijun Pan, Xiaowen Hu, Xiaodong Mei, Haiming Wei, Xiaoling Xu

《医学前沿（英文）》 2021年 第15卷 第3期   页码 486-494 doi: 10.1007/s11684-020-0824-3

摘要： Tocilizumab has been reported to attenuate the “cytokine storm” in COVID-19 patients. We attempted to verify the effectiveness and safety of tocilizumab therapy in COVID-19 and identify patients most likely to benefit from this treatment. We conducted a randomized, controlled, open-label multicenter trial among COVID-19 patients. The patients were randomly assigned in a 1:1 ratio to receive either tocilizumab in addition to standard care or standard care alone. The cure rate, changes of oxygen saturation and interference, and inflammation biomarkers were observed. Thirty-three patients were randomized to the tocilizumab group, and 32 patients to the control group. The cure rate in the tocilizumab group was higher than that in the control group, but the difference was not statistically significant (94.12% vs. 87.10%, rate difference 95% CI −7.19%–21.23%, = 0.4133). The improvement in hypoxia for the tocilizumab group was higher from day 4 onward and statistically significant from day 12 ( = 0.0359). In moderate disease patients with bilateral pulmonary lesions, the hypoxia ameliorated earlier after tocilizumab treatment, and less patients (1/12, 8.33%) needed an increase of inhaled oxygen concentration compared with the controls (4/6, 66.67%; rate difference 95% CI −99.17% to −17.50%, = 0.0217). No severe adverse events occurred. More mild temporary adverse events were recorded in tocilizumab recipients (20/34, 58.82%) than the controls (4/31, 12.90%). Tocilizumab can improve hypoxia without unacceptable side effect profile and significant influences on the time virus load becomes negative. For patients with bilateral pulmonary lesions and elevated IL-6 levels, tocilizumab could be recommended to improve outcome.

关键词： tocilizumab     coronavirus disease 2019 (COVID-19)     cytokine storm    

HTML PDF 收藏

标题 作者 时间 类型 操作

Beneficial metabolic activities of inflammatory cytokine interleukin 15 in obesity and type 2 diabetes

null

期刊论文

Cytokine storm and translating IL-6 biology into effective treatments for COVID-19

期刊论文

Inflammation and liver tumorigenesis

null

期刊论文

High-affinity T cell receptors redirect cytokine-activated T cells (CAT) to kill cancer cells

Synat Kang, Yanyan Li, Yifeng Bao, Yi Li

期刊论文

Molecular characterization of two suppressor of cytokine signaling 1 genes (

Xue XU,Jiannan ZHANG,Juan LI,Yajun WANG

期刊论文

Management of cytokine release syndrome related to CAR-T cell therapy

Hongli Chen, Fangxia Wang, Pengyu Zhang, Yilin Zhang, Yinxia Chen, Xiaohu Fan, Xingmei Cao, Jie Liu, Yun Yang, Baiyan Wang, Bo Lei, Liufang Gu, Ju Bai, Lili Wei, Ruili Zhang, Qiuchuan Zhuang, Wanggang Zhang, Wanhong Zhao, Aili He

期刊论文

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients

期刊论文

The relationship between progesterone and Th-related cytokines in plasma during early pregnancy in cows

Lei CHENG,Youdong XIN,Xiaohua LIU,Xiuzhong HU,Min XIANG,Dingfa WANG,Shuhong ZHAO

期刊论文

人工肝血液净化系统——一种针对COVID-19细胞因子风暴的有效救治方法

章益民, 俞亮, 汤灵玲, 朱梦飞, 金燕琪, 王周晗, 李兰娟

期刊论文

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

期刊论文

Keratin 5-Cre-driven deletion of

Jun Yang, Lianqing Wang, Yingzhi Huang, Keqiang Liu, Chaoxia Lu, Nuo Si, Rongrong Wang, Yaping Liu, Xue Zhang

期刊论文

Endothelial dysfunction in COVID-19 calls for immediate attention: the emerging roles of the endothelium in inflammation caused by SARS-CoV-2

Weijian Hang, Chen Chen, Xin A. Zhang, Dao Wen Wang

期刊论文

中药治疗新冠病毒肺炎的科学基础

梁丽娴, 潘胡丹, 黄虞枫, 范星星, 王婉莹, 何芳, 蔡俊, 周华, 刘良

期刊论文

新冠病毒肺炎抗体应答、细胞因子的动态变化及其与生存状况的关联 ——一项回顾性队列研究

刘莉, 陈亨贵, 李莹, 李辉军, 李娇元, 王意, 姚霜, 秦川, 童书韬, 袁旭, 罗霞, 缪小平, 潘安, 刘争, 程黎明

期刊论文

Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial

Dongsheng Wang, Binqing Fu, Zhen Peng, Dongliang Yang, Mingfeng Han, Min Li, Yun Yang, Tianjun Yang, Liangye Sun, Wei Li, Wei Shi, Xin Yao, Yan Ma, Fei Xu, Xiaojing Wang, Jun Chen, Daqing Xia, Yubei Sun, Lin Dong, Jumei Wang, Xiaoyu Zhu, Min Zhang, Yonggang Zhou, Aijun Pan, Xiaowen Hu, Xiaodong Mei, Haiming Wei, Xiaoling Xu

期刊论文